Improving oesophageal adenocarcinoma outcomes through understanding genomics and treatment toxicity.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1147118

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Oesophageal adenocarcinoma is an aggressive cancer, as most patients will not survive for more than 5 years. Therefore we need to find better ways to treat patients. In this study we will identify the DNA mutations in oesophageal cancers that were part of clinical trial. The data allow us to determine why some tumours responded well to therapy, and why some patients had serious side effects to the treatment. The results will help inform on selection of therapy for future patients.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $1,013,282.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chemotherapy | clinical patient management | genomics | oesophageal cancer | sequencing

Related Links